Endocrine Balance
UK drug firms pull out of NICE reviews at record
By Samoyed · 103
Endocrine Balance
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
By emily johnson · 102
Nutrient Synergy
FDA Pilot Aims to Accelerate U.S. Drug Trials
By emily johnson · 208
Somatic Drills
Pharma struggles as AI fraud erodes patient trust in calls
By Samoyed · 482 Views · September 16, 2026
Microbiome Diversity
Novo Nordisk drops name to sharpen focus amid Lilly rivalry
By emily johnson · 83
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
By emily johnson
Breast cancer drug Etcamah fails first-line trial test
By emily johnson
Biotechs lead fight against cancer
By emily johnson
Microbiome Diversity 
Microbiome Diversity 
Microbiome Diversity 
Microbiome Diversity 
FDA Pilot Aims to Accelerate U.S. Drug Trials
0 by emily johnson
In-Depth Analysis Pharmacy Landscape in Indonesia
0 by Samoyed
Ivonescimab Meets Overall Survival Goal in NSCLC
0 by emily johnson
Recovery Modalities
Sensorion gets green light for HearConnex trial
Sensorion's HearConnex trial gets green light for hearing loss treatment with gene therapy SENS-601.
September 4, 2026
Recovery Modalities
HiRO and Differentia Biotech collaborate on trial simulation
HiRO and Differentia Biotech collaborate on advanced clinical trial simulation models. Learn how this AI-driven partnership aims to...
August 31, 2026
Recovery Modalities
Daiichi Sankyo Begins Phase I DS1025 Trial
First patient dosing has begun in the Phase I DS1025 study , a trial that will assess an...
August 29, 2026
Editor's picks
Why Is Medicaid Member Engagement Essential for Health
Medicaid is a cornerstone of healthcare access for millions of Americans, including low-income families, seniors, and individuals with disabilities. While...
August 27, 2026
Pharma struggles as AI fraud erodes patient trust in calls
AI fraud is eroding patient trust in pharma calls, with scammers using voice cloning and spoofing to mimic legitimate pharmaceutical...
September 16, 2026
ESC 2026 AstraZeneca oral relaxin passes Phase II
AstraZeneca's AZD5462 shows promise in Phase II trial for chronic heart failure, improving cardiac function via relaxin pathway.
September 2, 2026
Pharma struggles as AI fraud erodes patient trust in calls
By Samoyed · Sep 16, 2026
ESC 2026 AstraZeneca oral relaxin passes Phase II
By Samoyed · Sep 2, 2026
Why Is Medicaid Member Engagement Essential for Health
By Samoyed · Aug 27, 2026
All Post
Endocrine Balance
UK drug firms pull out of NICE reviews at record
UK drug firms are pulling out of NICE reviews at record levels in 2026, raising questions about industry shifts or systemic issues in the appraisal process.
Samoyed 223 Views September 19, 2026
Endocrine Balance
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
The FDA has approved the first gene therapy, Fayuvi, for Sanfilippo syndrome type A, offering hope to affected children.
emily johnson 182 Views September 18, 2026
Nutrient Synergy
FDA Pilot Aims to Accelerate U.S. Drug Trials
The FDA's new pilot program aims to accelerate U.S. drug trials, reducing time from discovery to first-in-human studies.
emily johnson 158 Views September 17, 2026
Somatic Drills
Pharma struggles as AI fraud erodes patient trust in calls
AI fraud is eroding patient trust in pharma calls, with scammers using voice cloning and spoofing to mimic legitimate pharmaceutical outreach.
Samoyed 157 Views September 16, 2026
Endocrine Balance
Breast cancer drug Etcamah fails first-line trial test
AstraZeneca’s breast cancer drug Etcamah failed its first-line trial, SERENA-4, raising doubts about its potential as a frontline treatment for HR-positive pati
emily johnson 259 Views September 15, 2026
Microbiome Diversity
Novo Nordisk drops name to sharpen focus amid Lilly rivalry
Novo Nordisk drops its full name to become 'Novo,' sharpening focus against Eli Lilly in weight loss and diabetes treatments amid slowing growth.
emily johnson 123 Views September 14, 2026
Nutrient Synergy
AbbVie tests new approach for menstrual migraine treatment
AbbVie’s Qulipta becomes first oral CGRP inhibitor to succeed in phase 3 menstrual migraine trials, offering hope for resistant cases.
Samoyed 124 Views September 12, 2026
Endocrine Balance
Biotechs lead fight against cancer
Biotechs lead the fight against cancer with next-generation treatments and clinical trials.
emily johnson 281 Views September 11, 2026
Recovery Modalities
Bayer Moves Hyrnuo Into Frontline Lung Cancer
Bayer secured FDA approval for Hyrnuo lung cancer treatment, marking a major shift in frontline HER2-mutant NSCLC care based on new clinical data.
Samoyed 281 Views September 10, 2026
Microbiome Diversity
Bristol Myers reports progress in multiple myeloma trial
Bristol Myers reports progress in multiple myeloma trial with arlocabtagene autoleucel showing promise.
Samoyed 110 Views September 9, 2026